Dual specificity mitogen-activated protein kinase kinase 6 also known as MAP kinase kinase 6 (MAPKK 6) or MAPK/ERK kinase 6 is an
enzyme that in humans is encoded by the MAP2K6gene, on
chromosome 17.[5]
^Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K (Mar 1999). "The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway". Nature. 398 (6724): 252–6.
Bibcode:
1999Natur.398..252N.
doi:
10.1038/18465.
PMID10094049.
S2CID4421236.
^Sakurai H, Miyoshi H, Mizukami J, Sugita T (Jun 2000). "Phosphorylation-dependent activation of TAK1 mitogen-activated protein kinase kinase kinase by TAB1". FEBS Letters. 474 (2–3): 141–5.
doi:
10.1016/S0014-5793(00)01588-X.
PMID10838074.
S2CID30831863.
Tanaka S, Nakamura K, Takahasi N, Suda T (Dec 2005). "Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system". Immunological Reviews. 208: 30–49.
doi:
10.1111/j.0105-2896.2005.00327.x.
PMID16313339.
S2CID13811917.
Doza YN, Cuenda A, Thomas GM, Cohen P, Nebreda AR (May 1995). "Activation of the MAP kinase homologue RK requires the phosphorylation of Thr-180 and Tyr-182 and both residues are phosphorylated in chemically stressed KB cells". FEBS Letters. 364 (2): 223–8.
doi:
10.1016/0014-5793(95)00346-B.
PMID7750576.
S2CID25025858.
Maruyama K, Sugano S (Jan 1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1–2): 171–4.
doi:
10.1016/0378-1119(94)90802-8.
PMID8125298.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A, Sugano S (Oct 1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1–2): 149–56.
doi:
10.1016/S0378-1119(97)00411-3.
PMID9373149.
Dual specificity mitogen-activated protein kinase kinase 6 also known as MAP kinase kinase 6 (MAPKK 6) or MAPK/ERK kinase 6 is an
enzyme that in humans is encoded by the MAP2K6gene, on
chromosome 17.[5]
^Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K (Mar 1999). "The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway". Nature. 398 (6724): 252–6.
Bibcode:
1999Natur.398..252N.
doi:
10.1038/18465.
PMID10094049.
S2CID4421236.
^Sakurai H, Miyoshi H, Mizukami J, Sugita T (Jun 2000). "Phosphorylation-dependent activation of TAK1 mitogen-activated protein kinase kinase kinase by TAB1". FEBS Letters. 474 (2–3): 141–5.
doi:
10.1016/S0014-5793(00)01588-X.
PMID10838074.
S2CID30831863.
Tanaka S, Nakamura K, Takahasi N, Suda T (Dec 2005). "Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system". Immunological Reviews. 208: 30–49.
doi:
10.1111/j.0105-2896.2005.00327.x.
PMID16313339.
S2CID13811917.
Doza YN, Cuenda A, Thomas GM, Cohen P, Nebreda AR (May 1995). "Activation of the MAP kinase homologue RK requires the phosphorylation of Thr-180 and Tyr-182 and both residues are phosphorylated in chemically stressed KB cells". FEBS Letters. 364 (2): 223–8.
doi:
10.1016/0014-5793(95)00346-B.
PMID7750576.
S2CID25025858.
Maruyama K, Sugano S (Jan 1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1–2): 171–4.
doi:
10.1016/0378-1119(94)90802-8.
PMID8125298.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A, Sugano S (Oct 1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1–2): 149–56.
doi:
10.1016/S0378-1119(97)00411-3.
PMID9373149.